股票研究 /[Table_Date] 2026.01.28 收购 PUMA 29%股权，全球化布局注入 新动力 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 盛开(分析师) | 021-23154510 | shengkai@gtht.com | S0880525040044 | | 钟启辉(研究助理) | 021-23185686 | zhongqihui@gtht.com | S0880125042254 | 本报告导读： 安踏出资 15 亿欧元收购 PUMA 29%股份，成为最大股东。PUMA 业绩面临短期压 力，当前正处清货节奏。我们认为此次收购是安踏推进"单聚焦、多品牌、全球化" 战略的关键一步。 投资要点： | 财务摘要(百万人民币) | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入 | 70826 | 78410 | 85846 | 95707 | | (+/-)% | 13.6% | 10.7% | 9.5% | ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four Phase III trials in 2026 targeting five major indications. This development is expected to position Pfizer favorably in the competitive landscape of next-generation cancer immunotherapy [1][8]. - The collaboration between Pfizer and the company is anticipated to unlock significant global value for 707/PF'4404, serving as a key catalyst for the company's upward trajectory [1][8]. - The company is also increasing its R&D investments, with multiple pipelines expected to yield clinical data soon, enhancing the potential for external licensing opportunities [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. Projections for FY24A and FY25E are RMB 9,108 million and RMB 17,972 million, respectively, indicating a significant growth trajectory [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, reflecting a decline of 19.1% year-on-year, but is expected to rebound to RMB 2,090 million in FY24A and surge to RMB 9,741 million in FY25E, marking a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY25E is projected at RMB 3.84, with a price-to-earnings (P/E) ratio of 5.6, indicating a strong valuation relative to earnings [2][15]. Market Position and Shareholder Structure - The company's market capitalization stands at HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6%, indicating a concentrated ownership structure [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs (antibody-drug conjugates) as a unique advantage [1][8]. - The company has several promising candidates in its pipeline, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1), which are currently in Phase II trials in China [8][12]. Valuation and Forecast Adjustments - The report adjusts the financial forecasts for FY25E and FY26E, reflecting a slight increase in revenue expectations due to the anticipated success of the 707 program [12][13]. - The DCF valuation analysis estimates a per-share value of HKD 37.43, based on a weighted average cost of capital (WACC) of 10.11% and a perpetual growth rate of 2.0% [13][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four global Phase III trials in 2026 targeting five major indications. The combination of PD-(L)1/VEGF dual antibodies is expected to become a cornerstone of next-generation cancer immunotherapy, positioning Pfizer to leverage its internal pipeline synergy and strong clinical execution capabilities [1][8]. - The company is increasing its R&D investments, with several pipelines expected to yield clinical data soon. The core business fundamentals remain robust, providing a safety margin, and the company is projected to achieve significant revenue growth driven by its innovative pipeline [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. The projected sales revenue for FY25E is RMB 17,972 million, reflecting a substantial increase of 97.3% [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, with a year-on-year decline of 19.1%. However, the forecast for FY25E shows a significant increase to RMB 9,741 million, indicating a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY23A was RMB 0.64, expected to rise to RMB 3.84 in FY25E [2][15]. Market Position and Shareholder Structure - The company's market capitalization is approximately HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6% [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs as a unique advantage. The company plans to conduct multiple Phase III trials for various indications, including NSCLC and mCRC, with a focus on rapid patient recruitment [1][8]. - The ongoing clinical trials for other innovative products, such as 705 (PD-1/HER2) and 706 (PD-1/PD-L1), are also expected to contribute to the company's growth and potential licensing opportunities [8][12].

Investment Rating - The report maintains a rating of "Buy" for the company [1] Core Views - As an industry leader, the company's value is expected to undergo systematic re-evaluation driven by the gradual release of new product performance, the leading product quality of "good houses," and the unlocking of capital cycles through commercial REITs [2] Financial Summary - Total revenue is projected to be RMB 202.524 billion in 2023, with a year-on-year growth of 12.3%. However, it is expected to decline to RMB 185.154 billion in 2024, a decrease of 8.6%, and further decline in the following years [4] - Gross profit is expected to decrease from RMB 41.153 billion in 2023 to RMB 32.765 billion in 2024, with a net profit forecasted to drop from RMB 25.610 billion to RMB 15.636 billion in the same period [4] - The company’s PE ratio is projected to increase from 5.27 in 2023 to 7.78 in 2024, while the PB ratio is expected to decrease from 0.36 to 0.32 [4] Investment Recommendations - The report suggests maintaining a "Buy" rating, with an estimated EPS of RMB 1.18, 1.19, and 1.32 for 2025-2027. The target price is set at HKD 20.3 based on a PB of 0.5X for 2026 [8] - The transition between old and new projects is expected to drive performance recovery, with new investments concentrated in prime locations in first-tier and strong second-tier cities [8] - The company’s "good house" initiative is anticipated to lead industry trends, enhancing product strength and long-term competitive advantages [8] Business Operations - The company has established a multi-format commercial operation system centered on office buildings and shopping centers, with stable cash flow and continuous expansion [8] - The successful listing of the first commercial REITs in 2025 marks a breakthrough in the company's asset management strategy, enhancing capital efficiency and long-term valuation [8] Financial Analysis - The company is expected to maintain a strong financial position with a focus on cost control and stable dividend payouts [13] - The development segment contributes over 90% to profits, with a recovery in gross margins anticipated [13] - The company’s liquidity remains strong, with a stable dividend yield [11]

国信纺服观点： 1、标的概况：PUMA 现管理层正推动品牌复苏，短期产生一次性成本，致力于 2027 年恢复增长； 4、风险提示：关税政策不确定性；品牌形象受损；市场的系统性风险。 5、投资建议：看好集团多品牌全球化运营下，持续好于行业的成长潜力。此次安踏对 PUMA 的收购，是公司全 球化战略的进一步深化，PUMA 在全球运动鞋服市场份额领先，在多个专业运动项目以及欧洲等重点市场具有领 先地位和先进经验与安踏集团品牌矩阵有协同性和互补性；PUMA 虽然短期增长乏力、盈利承压，但现管理层正 推动品牌复苏，致力于 2027 年恢复增长，安踏加入后更有望焕发品牌新增长活力。我们维持盈利预测，预计公 司 2025-2027 年归母净利润分别为 132.1/139.3/155.8 亿元，可比口径的利润增长分别为+10.7%/5.5%/11.9% （2024 年剔除 Amer 上市和配售权益摊薄所得的可比口径利润为 119.3 亿元）。维持 107-112 港元目标价，对应 2026 年 20-21X PE，维持"优于大市"评级。 评论： 标的概况：PUMA 现管理层正推动品牌复苏，短期产生一次性成本，致力于 2027 ...

研究报告 Research Report 28 Jan 2026 安踏体育 ANTA SPORTS (2020 HK) 战略性收购 Puma 29.06%股权，继续推进单聚焦+多品牌+全球化战略 Strategic Acquisition of a 29.06% Stake in Puma to Further Advance the Strategy of Single Focus, Multi-Brand and Globalization [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$77.90 目标价 HK$91.40 HTI ESG 0.7-1.6-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$217.86bn / US$27.94bn 日交易额 (3 个月均值) US$93.59mn 发行股票数目 2,797mn 自由流通股 (%) 47% 1 年 ...

研究报告 Research Report 28 Jan 2026 安踏体育 ANTA SPORTS (2020 HK) [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$77.90 目标价 HK$91.40 HTI ESG 0.7-1.6-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$217.86bn / US$27.94bn 日交易额 (3 个月均值) US$93.59mn 发行股票数目 2,797mn 自由流通股 (%) 47% 1 年股价最高最低值 HK$104.40-HK$75.50 注：现价 HK$77.90 为 2026 年 01 月 27 日收盘价 资料来源： Factset 1mth 3mth 12mth 绝对值 -7.2% -13.3% -0.1% 绝对值（美元） -7.4% -13.6% -0.2% 相对 MSCI China -10.3% -11.6% -33.7% [Table_Profit] Rmb mn Dec ...

Investment Rating - The report maintains a "Buy" rating for Anta Sports (2020.HK) [2][8] Core Views - Anta Sports plans to acquire a 29.06% stake in PUMA for approximately €1.51 billion (about 12.28 billion RMB), representing a 62% premium over PUMA's previous closing price [8] - The acquisition aligns with Anta's strategy of "single focus, multi-brand, globalization," enhancing its brand matrix and global competitiveness [8] - PUMA's established brand presence and market positioning in various sports categories complement Anta's existing brands, potentially accelerating growth and resource synergy [8] - The acquisition is expected to be completed by the end of 2026, pending regulatory approvals, and will not affect Anta's annual dividend policy due to its strong cash position [8] Financial Forecasts - Revenue projections for Anta Sports are as follows: - 2024: 70.826 billion RMB - 2025: 78.479 billion RMB (growth rate of 10.8%) - 2026: 86.250 billion RMB (growth rate of 9.9%) - 2027: 94.396 billion RMB (growth rate of 9.4%) [2][9] - Net profit forecasts are: - 2024: 15.596 billion RMB - 2025: 13.139 billion RMB (decline of 15.8%) - 2026: 14.140 billion RMB (growth of 7.6%) - 2027: 15.846 billion RMB (growth of 12.1%) [2][9] - Earnings per share (EPS) estimates are: - 2024: 5.58 RMB - 2025: 4.70 RMB - 2026: 5.06 RMB - 2027: 5.67 RMB [2][9] - Price-to-earnings (P/E) ratios are projected at: - 2024: 13x - 2025: 15x - 2026: 14x - 2027: 12x [2][9] Market Positioning - PUMA is expected to rank third globally in sports brands with a 2.5% market share by 2024, following Nike and Adidas [8] - The acquisition is anticipated to enhance Anta's global strategy, leveraging PUMA's strengths in Europe, Latin America, and emerging markets [8]

证券研究报告 | 2026年01月27日 安踏体育（02020.HK） 收购彪马 29.06%股权，全球化战略进一步深化 公司研究·海外公司快评 纺织服饰·服装家纺 投资评级：优于大市（维持） 证券分析师： 丁诗洁 0755-81981391 dingshijie@guosen.com.cn 执证编码：S0980520040004 证券分析师： 刘佳琪 010-88005446 liujiaqi@guosen.com.cn 执证编码：S0980523070003 事项： 1 月 26 日，公司公告与 Pinault 家族的投资公司 Groupe Artémis 达成购股协议，以每股 35 欧元的价格收 购 PUMA SE 共计 43,014,760 股普通股（占其全部已发行股本约 29.06%），总对价 15.05 亿欧元（约合人 民币 122.78 亿元）。 国信纺服观点： 1、标的概况：PUMA 现管理层正推动品牌复苏，短期产生一次性成本，致力于 2027 年恢复增长； 4、风险提示：关税政策不确定性；品牌形象受损；市场的系统性风险。 5、投资建议：看好集团多品牌全球化运营下，持续好于行业的成长潜力。此次 ...

Investment Rating - The investment rating for Anta Sports is "Buy" [4] Core Views - Anta Sports plans to acquire 29.06% of PUMA SE shares at a cash price of €35 per share, representing a 62% premium over PUMA's previous closing price, with a total transaction value of €1.506 billion (approximately ¥12.278 billion) [1] - The acquisition aims to enhance Anta's brand matrix and strengthen its global presence, particularly in markets where PUMA has significant influence, such as Europe, Latin America, Africa, and India [1] - PUMA is currently experiencing a performance downturn, with a projected revenue decline of low double digits for the full year 2025, and a reported EBIT loss of €10.7 million for the first three quarters of 2025 [2] - Despite short-term challenges, the long-term outlook for PUMA is positive due to its strong brand assets and global influence, with expectations for performance improvement post-acquisition [2] Financial Performance Summary - Anta's main brand experienced slight fluctuations in performance due to a weak consumer environment, with Q4 revenue declining in low single digits, while Fila and other brands showed strong growth [3] - For 2025, Anta expects a revenue growth of 10.9% to ¥78.564 billion and a net profit of approximately ¥13.2 billion, reflecting an 11% increase compared to 2024 [3] - The company anticipates a revenue growth of over 10% for 2026, with a slight decrease in net profit margin [3] Financial Projections - Revenue projections for Anta Sports are as follows: - 2025: ¥78.564 billion - 2026: ¥87.019 billion - 2027: ¥96.465 billion [9] - Net profit projections are as follows: - 2025: ¥13.194 billion - 2026: ¥14.035 billion - 2027: ¥15.937 billion [9] - The expected P/E ratio for 2026 is 14 times [8]